Skip to main content

RXi Posts Sharp Drop in Q2 Losses

Premium

RXi Pharmaceuticals this week reported a sharp drop in its second-quarter losses as it reduced research and development spending.

The company's net loss in the quarter fell to $2.1 million, or $0.12 per share, from a year-ago loss of $5 million, or $0.37 per share.

R&D expenses shrank to $2.3 million from $3 million, while general and administrative costs edged up to $2.5 million from $2 million in the second quarter last year.

As of June 30, RXi had cash, cash equivalents, and short-term investments totaling $11.1 million.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.